Drug Pricing Strategies
Expert articles and analysis related to drug pricing strategies.
AI Summary — Last 30 Days
In the past 30 days, the Trump administration's focus on drug pricing reform has intensified with new programs aimed at addressing prescription drug costs as part of broader efforts to enhance value-based care (VBC) and site-neutral payments. The Center for Medicare & Medicaid Innovation (CMMI) under Dr. Mehmet Oz and Abe Sutton is exploring innovative payment models that prioritize population health management and emphasize cost transparency, significantly impacting accountable care organizations (ACOs) and health systems. Additionally, strategies around Medicaid outpatient prescription drug spending are evolving, with implications for long-term cost management in healthcare, as highlighted by KFF’s recent reports on trends affecting health costs and pricing transparency KFF Insights and prescription drug policies KFF Prescription Drugs.
Related Articles
Pills, Policy and Pressure: Why Ending Drug Shortages Must Be Pharmacy’s Strategic Priority in 2026
Drug shortages have become a defining challenge for health systems, requiring pharmacy leaders to move beyond reactive management and adopt integrated strategies that build long-term supply resilience...
What’s new with PBMs?
For physicians, the growing influence of pharmacy benefit managers is affecting how easily they can prescribe medications, how much patients pay out of pocket and how long treatment takes to begin, ac...
IRA Litigation: Pharma’s Failed Challenges To Medicare Drug Pricing
IRA Litigation: Pharma’s Failed Challenges To Medicare Drug Pricing Health Affairs
STAT+: Pharmalittle: We’re reading about Trump and drug prices, biotechs pushing back, and more
Reining in drug prices has been a priority for both the Trump and Biden administrations, but Trump is getting more credit for his efforts, polls show
Poll: Public Worries About Prescription Drug Costs Reach New High; Most Across Political Parties Want Government to Do More to Regulate Prices
As the Trump administration promotes its new TrumpRx website and other efforts to lower prescription drug prices, a growing majority of the public worries about being able to afford prescription drugs...
Public Views on Prescription Drug Costs: Regulation, Affordability and TrumpRx
Amid the Trump administration's focus on lowering prescription drug costs, including its new TrumpRx website, KFF's Health Tracking Poll finds that most Americans (59%) are worried about affording pre...
STAT+: Trump is getting more credit than Biden for efforts to lower drug prices
Trump is drawing more attention to his efforts to lower drug prices, like TrumpRx.
Key Facts About Medicare Drug Price Negotiation
Under the Medicare Drug Price Negotiation Program, the federal government negotiates prices with drug companies for certain high-cost drugs covered under Medicare Part B and Part D. This brief provide...
Jeff Davis Provides Insight on States Pushing Back Against Drugmaker Limits on 340B Contract Pharmacies
Jeff Davis Provides Insight on States Pushing Back Against Drugmaker Limits on 340B Contract Pharmacies Bass, Berry & Sims PLC
STAT+: Pharmalittle: We’re reading about the FDA warning Novo Nordisk, Lilly investing in China, and more
The Trump administration push for lower U.S. drug prices helped Astellas secure higher pricing for its new eye medicine in Japan